Comparison of in vitro and in vivo release characteristics of sustained release ofloxacin microspheres

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 7, Issue 2, 2000, Pages 77-81

  Abazinge, Michael ^a   Jackson, Tanise ^a   Yang, Qing ^a   Owusu Ababio, Godfried ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Biodegradable Polymer; Microspheres; Ofloxacin; Rat; Solvent Evaporation

Indexed keywords

ANTIINFECTIVE AGENT; MICROSPHERE; OFLOXACIN;

ARTICLE; BIODEGRADATION; BIOFILM; DRUG BLOOD LEVEL; DRUG RELEASE; EMULSION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUSTAINED RELEASE PREPARATION;

EID: 0034047846     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.1080/107175400266632     Document Type: Article

References (19)

1. Akiyama, H., Kanzaki, H., Tada, J., and Arata, J. 1996. Staphylococcus aureus infection on cut wounds in the mouse skin: experimental staphylococcal botryomycosis. J. Dermatol. Sci. 1:234-238.
2. Anwar, H., Dasgupta, M. K., and Costerton, J. W. 1990. Testing the susceptibility of bacteria in biofilms to antibacterials. Antimicrob. Agents Chemother. 34:2043-2046.
3. Cles, R., Dusart Y., Dupont J. C., Jeanbaptiste B., et al. 1986. Diffusion of oral ofloxacin chromatography method. Infection 14 (suppl. 4):S263-S265.
4. Gentry, L. O. 1991. Ofloxacin versus parenteral therapy for chronic ostemyelitis. Antimicrob. Agents Chemother. 35:538-541.
5. Gristina, A. G., Oga, M., Webb, L. X., and Hobgood, C. D. 1985. Adherent bacterial colonization in the pathogenesis of osteomyelitis. Science 228:990-993.
6. Lamp, K. C., Bailey, E. M., and Rybak, M. J. 1992. Ofloxacin clinical pharmacokinetics. Clin. Pharmacokinet. 22:32-46.
7. Lew, D. P., and Waldvogel, F. A. 1995. Quinolones and osteomyelitis: state of the art. Drugs 49 (suppl. 2):100-111.
8. May, T. B., Shinabarger, D., Maharaj, R., et al. 1991. Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin. Microbiol. Rev. 4:191-206.
9. Miller, R. A., Brady, J. M., and Cutright, D. E. 1977. Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. J. Biomed. Mater. Res. 11:711- 719.
10. Molinari, G., Pugliese, V., Schito, G. C., and Guzman, C. A. 1996. Bacteria involved in the blockage of biliary stents and their susceptibility to antibacterial agents. Eur. J. Clin. Microbiol. Infect. Dis. 15:88-92.
11. Morris, W., Steinhoff, M. C., and Russell, P. K. 1994. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 12:1-7.
12. Ohgaki, N. 1994. Bacterial biofilm in chronic airway infection. Kansenshogaku Zasshi 68:138-151.
13. Owusu-Ababio, G., and Rogers, J. A. 1996. Formulation and release kinetics of cephalexin monohydrate from biodegradable polymeric microspheres. J. Microencapsulation 13:195-205.
14. Stratton, C. 1992. Fluoroquinolone antibiotics: properties of the class and individual agents. Clin. Therapeutics 14:348-356.
15. Suay, D., Tack, K., and Flor, S. 1991. Safety and pharmacokinetics of a single intravenous ofloxacin in healthy volunteers. Int. J. Clin. Pharm. Res. 11:203-209.
16. Walker, R. C., and Wright, A. J. 1991. Symposiun on antimicrobial agents-Part IV. The fluoroquinolones. Mayo Clin. Proc. 66:1249-1259.
17. Ward, K. H., Olson, M. E., Lam, K., and Costerton, J. W. 1992. Mechanism of persistent infection associated with peritoneal implants. J. Med. Microbiol. 36:406-413.
18. Wolf, R., Ebert, R., Dunky, A. et al. 1984. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers. J. Antimicrobial Chemotherapy (suppl. C):63-69.
19. Yuh, I. H., Nightingale, C. H., Quintiliani, R., and Sweeney, K. R. 1991. Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 35:384-386.